Literature DB >> 27018978

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Laura A Volpicelli-Daley1, Deniz Kirik2, Lindsay E Stoyka3, David G Standaert3, Ashley S Harms3.   

Abstract

Animal models of Parkinson's disease (PD) are important for understanding the mechanisms of the disease and can contribute to developing and validating novel therapeutics. Ideally, these models should replicate the cardinal features of PD, such as progressive neurodegeneration of catecholaminergic neurons and motor defects. Many current PD models emphasize pathological forms of α-synuclein, based on findings that autosomal dominant mutations in α-synuclein and duplications/triplications of the SNCA gene cause PD. In addition, Lewy bodies and Lewy neurites, primarily composed of α-synuclein, represent the predominant pathological characteristics of PD. These inclusions have defined features, such as insolubility in non-ionic detergent, hyperphosphorylation, proteinase K sensitivity, a filamentous appearance by electron microscopy, and β-sheet structure. Furthermore, it has become clear that Lewy bodies and Lewy neurites are found throughout the peripheral and central nervous system, and could account not only for motor symptoms, but also for non-motor symptoms of the disease. The goal of this review is to describe two new α-synuclein-based models: the recombinant adeno-associated viral vector-α-synuclein model and the α-synuclein fibril model. An advantage of both models is that they do not require extensive crossbreeding of rodents transgenic for α-synuclein with other rodents transgenic for genes of interest to study the impact of such genes on PD-related pathology and phenotypes. In addition, abnormal α-synuclein can be expressed in brain regions relevant for disease. Here, we discuss the features of each model, how each model has contributed thus far to our understanding of PD, and the advantages and potential caveats of each model. This review describes two α-synuclein-based rodent models of Parkinson's disease: the rAAV-α-synuclein model and the α-synuclein fibril model. The key features of these models are described, and the extent to which they recapitulate features of PD, such as α-synuclein inclusion formation, loss of dopaminergic synapses in the striatum, motor defects, inflammation, and dopamine neuron death. This article is part of a special issue on Parkinson disease.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  zzm321990AAVzzm321990; Lewy bodies; Lewy neurites; Parkinson's disease; fibril; α-synuclein

Mesh:

Substances:

Year:  2016        PMID: 27018978      PMCID: PMC5040622          DOI: 10.1111/jnc.13627

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  111 in total

1.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

2.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

Review 3.  New insights into cellular α-synuclein homeostasis in health and disease.

Authors:  Ulf Dettmer; Dennis Selkoe; Tim Bartels
Journal:  Curr Opin Neurobiol       Date:  2015-08-15       Impact factor: 6.627

4.  Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.

Authors:  D Luke Fischer; Sara E Gombash; Christopher J Kemp; Fredric P Manfredsson; Nicole K Polinski; Megan F Duffy; Caryl E Sortwell
Journal:  Methods Mol Biol       Date:  2016

5.  TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity.

Authors:  Mickael Decressac; Bengt Mattsson; Pia Weikop; Martin Lundblad; Johan Jakobsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

6.  The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Authors:  Oleg S Gorbatyuk; Shoudong Li; Layla F Sullivan; Weijun Chen; Galina Kondrikova; Fredric P Manfredsson; Ronald J Mandel; Nicholas Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

7.  Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system.

Authors:  Nikolaus R McFarland; Jeng-Shin Lee; Bradley T Hyman; Pamela J McLean
Journal:  J Neurochem       Date:  2009-02-24       Impact factor: 5.372

8.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

9.  Genomewide association study for susceptibility genes contributing to familial Parkinson disease.

Authors:  Nathan Pankratz; Jemma B Wilk; Jeanne C Latourelle; Anita L DeStefano; Cheryl Halter; Elizabeth W Pugh; Kimberly F Doheny; James F Gusella; William C Nichols; Tatiana Foroud; Richard H Myers
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

10.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  44 in total

Review 1.  Gene therapy approaches in the non-human primate model of Parkinson's disease.

Authors:  D Pignataro; D Sucunza; A J Rico; I G Dopeso-Reyes; E Roda; A I Rodríguez-Perez; J L Labandeira-Garcia; V Broccoli; S Kato; K Kobayashi; José L Lanciego
Journal:  J Neural Transm (Vienna)       Date:  2017-01-27       Impact factor: 3.575

2.  An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease1.

Authors:  Velmarini Vasquez; Joy Mitra; George Perry; K S Rao; Muralidhar L Hegde
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

3.  Retina as a Model to Study In Vivo Transmission of α-Synuclein in the A53T Mouse Model of Parkinson's Disease.

Authors:  Najiba Mammadova; Thierry Baron; Jérémy Verchère; Justin J Greenlee; M Heather West Greenlee
Journal:  Methods Mol Biol       Date:  2021

4.  Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.

Authors:  Joseph R Patterson; Megan F Duffy; Christopher J Kemp; Jacob W Howe; Timothy J Collier; Anna C Stoll; Kathryn M Miller; Pooja Patel; Nathan Levine; Darren J Moore; Kelvin C Luk; Sheila M Fleming; Nicholas M Kanaan; Katrina L Paumier; Omar M A El-Agnaf; Caryl E Sortwell
Journal:  Neurobiol Dis       Date:  2019-07-02       Impact factor: 5.996

5.  Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.

Authors:  Poonam Thakur; Ludivine S Breger; Martin Lundblad; Oi Wan Wan; Bengt Mattsson; Kelvin C Luk; Virginia M Y Lee; John Q Trojanowski; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

6.  Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.

Authors:  Ashley S Harms; Aaron D Thome; Zhaoqi Yan; Aubrey M Schonhoff; Gregory P Williams; Xinru Li; Yudong Liu; Hongwei Qin; Etty N Benveniste; David G Standaert
Journal:  Exp Neurol       Date:  2017-11-16       Impact factor: 5.330

7.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 8.  New Developments in Genetic rat models of Parkinson's Disease.

Authors:  Rose B Creed; Matthew S Goldberg
Journal:  Mov Disord       Date:  2018-02-08       Impact factor: 10.338

9.  Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.

Authors:  Shelby Shrigley; Fredrik Nilsson; Bengt Mattsson; Alessandro Fiorenzano; Janitha Mudannayake; Andreas Bruzelius; Daniella Rylander Ottosson; Anders Björklund; Deirdre B Hoban; Malin Parmar
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 10.  Adeno-Associated Virus Expression of α-Synuclein as a Tool to Model Parkinson's Disease: Current Understanding and Knowledge Gaps.

Authors:  Taylor E Huntington; Rahul Srinivasan
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.